Stay updated with breaking news from Single Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and
IRLAB Therapeutics AB announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy - a condition...
BETHESDA, Md., Feb. 27, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...
Island Pharmaceuticals Ltd (ASX:ILA) has secured a loan facility for the 2024 financial year with Radium Capital, providing an injection of funding ahead of...
GHENT, Belgium, December 14, 2023--Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).